The open benchmark competition will evaluate the ability of AI-powered virtual cell models to generalize to new cell contexts for therapeutic applications.

Investing.com -- Lineage Cell Therapeutics Inc (NYSE American:NYSE: LCTX) stock rose 2.7% after the company announced positive 36-month results from a Phase 1/2a clinical study of its RG6501 ...